Heterogeneity of Dendritic Cells in Colon and Non-small Cell Lung Cancer
TUM-DC
1 other identifier
observational
64
1 country
2
Brief Summary
Prospective study with the use of biological samples. The centers involved are the Thoracic Surgery and Surgery 1 Units of the San Gerardo Hospital in Monza.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2021
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 9, 2021
CompletedFirst Submitted
Initial submission to the registry
February 17, 2021
CompletedFirst Posted
Study publicly available on registry
March 9, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 9, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 9, 2026
CompletedJanuary 2, 2024
December 1, 2023
5 years
February 17, 2021
December 29, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Single cell bioinformatics analysis RNA-seq
For the analysis of single-cell RNA-seq data we will exploit the most recent methodologies provided by both 10x Genomics and custom R / Python scripts to perform the identification and characterization of cell subsets.
Until the end of the study (approximately 5 years).
Single cell RNA-seq library preparation and sequencing.
10,000 cells for each sample will be loaded on an instrument called Chromium 10X (10x genomics).
Until the end of the study (approximately 5 years).
Secondary Outcomes (2)
Spatial distributions of DC subtypes in the tumor microenvironment
Until the end of the study (approximately 5 years).
Correlation between subtypes of myeloid cells present in the tumor microenvironment and survival
Until the end of the study (approximately 5 years).
Study Arms (1)
Patients with NSCLC or with colon cancer
The subjects are men or women with aged more than 18 years suffering from colon or lung cancer; The lesions are more than 1 cm. They are also able to give informed consent. The pathologist will sample the material and select the tissue that can be used for the experiment after having taken all that is needed for diagnostic purposes. The research sample will be placed in test tubes and kept on ice. It will then be sent to University of Milano-Bicocca laboratory whrere It will analyze approximately 60 patients for immunofluorescence studies and 4 patients for single cell transcriptomic analyzes
Interventions
1. Sample collection: Myeloid cell purification + Single cell sequencing 2. Primary analysis: QC sequencing data + Reads alignment + UMI quantification 3. Bioinformatics analysis: Quality Control (Number of genes, UMI content,%mitochondrial genes, % riboprotein genes,Filtering low quality cells) + Normalization and scaling (Normalization, Remove unwanted sources of variation, HVG detection) + PCA Clustering Markers (PCA and PC selection, Clustering, t-SNE, Differential expression for markers identification) 4. Validation: FACS analysis + immunohistochemistry
Eligibility Criteria
Patients with NSCLC (primary tumor, adjacent healthy tissue, blood) or colon cancer (primary tumor, normal adjacent tissue, blood)
You may qualify if:
- men and women aged ≥18 years;
- clinical diagnosis confirmed by common investigations to establish the presence of colon or lung cancer;
- lesions\> 1 cm;
- legal capacity to give informed consent in accordance with ICH / EU GCP and national / local regulations.
You may not qualify if:
- pregnancy;
- presumed pregnancy;
- known coagulation defects;
- alcohol or drug abuse
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
ASST Monza-C. CHIRURGIA GENERALE E D'URGENZA I
Monza, Italy
ASST Monza-Ospedale San Gerardo, S.C. Chirurgia Toracica
Monza, Italy
Related Publications (5)
Gornati L, Zanoni I, Granucci F. Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines. Front Immunol. 2018 Jun 27;9:1484. doi: 10.3389/fimmu.2018.01484. eCollection 2018.
PMID: 29997628BACKGROUNDBottcher JP, Reis e Sousa C. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity. Trends Cancer. 2018 Nov;4(11):784-792. doi: 10.1016/j.trecan.2018.09.001. Epub 2018 Sep 29.
PMID: 30352680BACKGROUNDHildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008 Nov 14;322(5904):1097-100. doi: 10.1126/science.1164206.
PMID: 19008445BACKGROUNDEisenbarth SC. Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2019 Feb;19(2):89-103. doi: 10.1038/s41577-018-0088-1.
PMID: 30464294BACKGROUNDMingozzi F, Spreafico R, Gorletta T, Cigni C, Di Gioia M, Caccia M, Sironi L, Collini M, Soncini M, Rusconi M, von Andrian UH, Chirico G, Zanoni I, Granucci F. Prolonged contact with dendritic cells turns lymph node-resident NK cells into anti-tumor effectors. EMBO Mol Med. 2016 Sep 1;8(9):1039-51. doi: 10.15252/emmm.201506164. Print 2016 Sep.
PMID: 27406819BACKGROUND
Biospecimen
Samples from patients with NSCLC: primary tumor, adjacent healthy tissue, blood. Samples from patients with colon cancer: primary tumor, normal adjacent tissue, blood.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2021
First Posted
March 9, 2021
Study Start
February 9, 2021
Primary Completion
February 9, 2026
Study Completion
February 9, 2026
Last Updated
January 2, 2024
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share